MRM Proteomics Inc. partners with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments.
This will be the first immuno-MALDI test to measure the activity of multiple cancer-associated proteins in patients’ tumours. Potentially, this could transform the selection of cancer treatments by providing direct insight into the mechanisms of disease progression and appropriate drug targets on a patient-by-patient basis.
“Exactis is pleased to partner with MRM-P in this project and support a small to medium-sized enterprise (SME) in its goals to provide innovative molecular testing technologies that support the evolution of precision oncology. Support of diagnostic technology development in precision oncology that capitalizes on local expertise helps the expansion of the biotechnology/medical technology industry in Quebec” says Mr. Richard Fajzel, president and CEO of Exactis innovation.
MRM Proteomics will use their proprietary immunoMALDI technology to analyze breast and colorectal tumour samples obtained through Exactis’s Personalize My Treatment patient registry. Once validated, the clinically-applicable test will be used to characterize immune signatures and tumour mutation profiles to screen patients for response to immuno-oncologic cancer treatments.
“Proteomics is in a position to realize the promise of precision medicine. Proteins are the effectors of biological processes in the cells and the targets of most drugs. We need to look to proteins for the next step in precision medicine” says Dr. Christoph Borchers, chief scientific officer for MRM Proteomics.
A significant advantage for clinicians and patients is that the innovative response-prediction tool will enable matching of patients with the most appropriate treatment as early as possible, which increases the chances of survival and avoids exposure to side effects from ineffective treatments.
“This is the core potential of precision medicine with proteomics — the ability to more accurately determine the right treatment up front means better outcomes for cancer patients” says Dr. Gerald Batist, co-founder and scientific director of Exactis Innovation and director of the Segal Cancer Centre at the Jewish General Hospital.
The partnership builds on recent advancements in precision medicine, molecular assays, quantitative proteomics and proteo-genomics and serves to advance Exactis’s mission to accelerate the translation of precision oncology into clinical care. The work also fits with MRM Proteomics’s focus on delivering high-quality proteomics technologies for research and clinical settings.
“MRM Proteomics is excited to develop biomarker assays for important cancer proteins with Exactis to facilitate the translation of the patented iMALDI test to the clinic where it can benefit patients,” says Claude Leduc, President and CEO of MRM Proteomics.
“The proteomics field is rapidly evolving, making it possible to generate highly accurate and reproducible quantification of important oncogenic proteins to guide treatment. This project benefits from Exactis’s access to a large number of clinical samples and high-quality clinical data and represents a remarkable opportunity to realize the potential of proteomics in the clinic,” he adds.
The validated proteomic assay is anticipated to lead to more effective therapy choice with improved outcomes for cancer patients while saving substantial costs associated with the use of ineffective treatments. This will also apply in a pharmaceutical research setting by providing a resourceful way to select appropriate patient sub-populations for precision medicine clinical trials, expediting FDA approvals, and introducing new therapeutic options to the clinic faster.